Incorrect password
evipedia.ai Suggest Edit

DFPP vs. TPE for Health & Longevity

Evidence Review created on 04/28/2026 using AI4L / Opus 4.7

Also known as: Double Filtration Plasmapheresis vs. Therapeutic Plasma Exchange, Cascade Plasmapheresis vs. Plasma Exchange, DFPP vs. PLEX, DFPP vs. PE

Motivation

Two extracorporeal blood-purification procedures have moved from rare-disease medicine into the longevity space: therapeutic plasma exchange and double filtration plasmapheresis. Both rest on the idea that aged plasma carries inflammatory and senescence-promoting factors whose mechanical removal from the bloodstream may improve tissue function.

Therapeutic plasma exchange is the modality used in the small human trials reporting reductions in epigenetic biological age, and is the established procedure for several autoimmune and neurological indications. Double filtration plasmapheresis, originally developed in Japan in the 1980s for severe lipid disorders, has accumulated decades of clinical safety data, uses far less replacement fluid, and has begun appearing in longevity-clinic protocols as a putatively gentler alternative.

This review compares the two procedures side by side across mechanism, evidence base, safety profile, sourcing and quality considerations, and practical access factors relevant to anyone evaluating either as part of a longevity strategy. The comparison aims to clarify where the procedures genuinely differ, where the evidence base for each is stronger or weaker, and where marketing claims have outpaced the published data.

Benefits - Risks - Protocol - Conclusion

A curated selection of high-quality resources providing accessible overviews of double filtration plasmapheresis (DFPP) and therapeutic plasma exchange (TPE) in the context of health and longevity.

  • Modern Vampirism: “Young Blood” Transfusions - Peter Attia

    Critical assessment of the broader plasma-exchange longevity space from a physician-scientist perspective, noting that supporting evidence for these treatments in healthy humans is “virtually nonexistent” for longevity claims, referencing the FDA’s 2019 warning against plasma transfusions for rejuvenation, and emphasizing the distinction between legitimate medical uses of TPE and unproven longevity marketing that increasingly bundles DFPP and TPE together.

  • Unlocking the Keys to Longevity by Understanding the Root Causes of Aging, with Mark Hyman - Chris Kresser

    Podcast conversation in which Mark Hyman describes undergoing plasmapheresis himself and discusses how plasma-filtration procedures are increasingly used to remove inflammatory compounds and damaged proteins, framing the procedure as the human analog of the Conboy laboratory’s blood-dilution experiments.

  • The Prospect of Human Age Reversal - William Faloon

    Comprehensive overview of plasma-exchange research for age reversal, covering the Buck Institute’s TPE clinical trial, Dr. Dobri Kiprov’s apheresis protocols, the AMBAR Alzheimer trial, and the mechanistic rationale for removing age-accumulated plasma factors. The article frames TPE rather than DFPP as the modality with active human longevity data.

  • Understanding DFPP: Treatment for Enhanced Health - AddLife

    Practitioner-oriented blog post describing how DFPP differs from conventional plasma exchange, walking through the two-stage filtration mechanism, the selective removal of pathogenic macromolecules while preserving beneficial plasma components, and the indications for which the procedure is most often used.

  • DFPP Therapy: Blood Detox and Cellular Renewal - ArokaGO

    Practitioner-oriented article explaining how DFPP differs from conventional TPE in technical terms, covering the two-stage filtration process, the selective removal of large molecules such as oxidized lipids, immune complexes, and lipoproteins, and the conservation of albumin and immunoglobulins that distinguishes DFPP from albumin-replacement TPE.

Rhonda Patrick (foundmyfitness.com) has commented on the underlying Conboy plasma-dilution research on social media but has no dedicated long-form content comparing DFPP and TPE. Andrew Huberman (hubermanlab.com) does not have dedicated content on either procedure.

Grokipedia

  • Plasmapheresis

    Grokipedia’s article covers the broader plasmapheresis category, including therapeutic plasma exchange, its centrifugal and membrane-filtration variants, indications across autoimmune and neurological disorders, session parameters, and a brief mention of experimental longevity applications. No dedicated comparative entry contrasting DFPP and TPE was identified.

Examine

No dedicated Examine article for DFPP, TPE, or any direct comparison exists as of April 2026. Examine.com does not typically cover medical devices or extracorporeal procedures.

ConsumerLab

No dedicated ConsumerLab article for DFPP, TPE, or any direct comparison exists as of April 2026. ConsumerLab does not typically cover medical devices or extracorporeal procedures.

Systematic Reviews

A summary of systematic reviews and meta-analyses relevant to the comparative evaluation of double filtration plasmapheresis and therapeutic plasma exchange.

Mechanism of Action

Both procedures rest on the premise that circulating plasma factors – inflammatory cytokines, autoantibodies, immune complexes, oxidized lipids, and senescence-associated secretory phenotype (SASP, the cocktail of inflammatory proteins released by aged or damaged “senescent” cells) proteins – accumulate with age and disease, and that mechanically removing them may improve downstream tissue function. The two modalities differ substantially in how they accomplish this.

Therapeutic Plasma Exchange (TPE): Whole blood is drawn through a vascular access point and routed through either a centrifugal device (which spins blood at differential densities) or a membrane plasma separator (a hollow-fiber filter). Plasma is collected and discarded; cellular components are returned to the patient along with a replacement fluid – typically 5% albumin in saline, fresh frozen plasma (FFP, donor plasma frozen shortly after collection to preserve clotting factors), or a combination. Because the entire plasma fraction is removed, TPE non-selectively eliminates everything dissolved in plasma, including beneficial proteins (immunoglobulins, clotting factors), and these must be replaced through the substitution fluid. A standard session exchanges 1-1.5 plasma volumes (40-60 mL/kg) over 2-3 hours.

Double Filtration Plasmapheresis (DFPP): Whole blood passes through a primary plasma separator (identical to membrane TPE), but the separated plasma is then routed through a second fractionator filter with a defined molecular-weight cutoff (typically around 30-60 kDa). Large molecules – LDL (low-density lipoprotein, the “bad cholesterol” particle that carries cholesterol from the liver to tissues) particles, immunoglobulins (IgG ~150 kDa, IgM ~900 kDa), fibrinogen, immune complexes – are retained and discarded; smaller proteins, including albumin (~66 kDa), pass through and are returned to the patient. This selective removal eliminates the need for large-volume albumin replacement, conserves the patient’s own physiological proteins, and reduces (though does not eliminate) the risk of donor-product reactions. Modern DFPP systems can process 1-2× the plasma volume per session.

The mechanistic rationale for longevity applications, articulated by Mehdipour, Conboy, and colleagues at UC Berkeley, is that simply diluting old plasma – without infusing young blood – attenuates age-elevated systemic regulators. In their 2020 mouse model, exchange with saline-albumin “neutral” plasma improved muscle repair, hippocampal neurogenesis, and liver function. The proteomic re-setting of several core inflammation and growth-control pathways – TLR4 (an immune-receptor signal that detects damage and triggers inflammation), JAK-STAT (a relay that translates cytokine signals into gene activation), MAPK (a stress- and growth-response cascade), TGF-beta (a tissue-remodeling and immune-regulating signal), and NF-κB (a master switch for inflammatory genes) – has been proposed as the molecular mechanism. Whether DFPP – which removes far less albumin and immunoglobulin per session – achieves the same systemic dilution effect remains scientifically contested.

Competing mechanistic perspectives exist. Critics, including investigators outside the apheresis field, argue that single-session removal of long-lived plasma proteins is followed within days to weeks by re-equilibration from extravascular compartments, and that sustained reductions require repeated sessions whose long-term metabolic consequences are not fully characterized. Proponents counter that the multi-omic signal observed in placebo-controlled trials (described in Emerging Research) reflects a durable shift even after a single course, and that DFPP’s preservation of host albumin and immunoglobulins may reduce iatrogenic harm relative to TPE.

As neither DFPP nor TPE is a pharmacological compound, half-life, CYP (cytochrome P450, the family of liver enzymes responsible for metabolizing most drugs) metabolism, and tissue distribution are not directly applicable. The relevant kinetic parameter is the half-life of the molecules being removed: IgG re-equilibrates over 3-4 weeks, fibrinogen over 3-5 days, LDL over 2-5 days. Treatment cycles are designed around these recovery curves.

Historical Context & Evolution

Therapeutic plasma exchange entered clinical medicine in the 1950s as a manual technique for hyperviscosity syndromes (conditions where the blood is abnormally thick due to excess plasma proteins) and was systematized through the 1970s with the development of automated centrifugal devices. Membrane-based plasma separation followed in the early 1980s. The American Society for Apheresis (ASFA, the main professional society of apheresis practitioners; its members derive direct revenue from performing the procedures it grades) has maintained evidence-graded indications since 1986, with the most recent guidelines (10th edition) recognizing TPE as Category I (first-line) therapy for thrombotic thrombocytopenic purpura (a rapidly fatal blood-clotting disorder, TTP), Guillain-Barré syndrome (GBS, an autoimmune attack on peripheral nerves causing paralysis), myasthenia gravis (MG) crisis, anti-glomerular basement membrane disease (an autoimmune kidney disease where antibodies attack the kidney’s filtering membrane, anti-GBM), and several other indications.

Double filtration plasmapheresis was developed in Japan in the early 1980s by Agishi and colleagues, motivated specifically by the desire to perform selective macromolecular removal without the donor-product burden of conventional TPE. Mabuchi and colleagues published the first large series in homozygous familial hypercholesterolemia (FH, an inherited disorder causing extremely high LDL cholesterol from birth) (PMID 3463306, 1986), and the technique spread through Japan, Europe, and parts of Asia for lipid disorders and autoimmune indications. DFPP did not gain widespread adoption in North America, where centrifugal TPE with albumin replacement remains the dominant modality.

The longevity application of plasma exchange emerged from heterochronic parabiosis research at Stanford and UC Berkeley in the 2000s and 2010s, where investigators showed that joining the circulations of young and old mice rejuvenated old tissues. The 2020 Mehdipour et al. paper reframed the field by demonstrating that dilution of old plasma – not infusion of young plasma – was sufficient for the rejuvenation effect, immediately implicating TPE-like procedures as candidate longevity interventions. The 2022 Kim, Kiprov, Conboy et al. clinical study and the 2025 Buck Institute placebo-controlled trial extended this to humans, exclusively using TPE rather than DFPP.

Historical research on DFPP for longevity is essentially absent: the technique was not designed with aging in mind, and its adoption in longevity clinics is a recent off-label transposition rather than the result of dedicated trials. Claims that DFPP is the “evolved” or “superior” longevity modality reflect commercial positioning by clinics that offer it, not published comparative head-to-head data in healthy older adults. Conversely, claims that TPE has been “validated” for longevity are also overstated: the supporting human trials are small, single-center, and led by investigators with commercial stakes in apheresis services.

Expected Benefits

High 🟩 🟩 🟩

Antibody Removal in Severe Autoimmune Disease (TPE)

TPE’s strongest evidence base is in conditions where rapid removal of circulating autoantibodies is life-saving: thrombotic thrombocytopenic purpura, Guillain-Barré syndrome, myasthenia gravis crisis, and anti-glomerular basement membrane disease. ASFA Category I guidelines (issued by the professional society whose members derive direct revenue from performing apheresis), Cochrane reviews, and large meta-analyses support TPE as first-line in these settings. While these indications are not the primary lens of a longevity audience, they establish that the procedure can produce durable, measurable physiological changes when performed at appropriate intensity.

Magnitude: In Guillain-Barré syndrome, TPE roughly halves time to motor recovery vs. supportive care; in TTP, plasma exchange reduces mortality from ~90% to <20%.

LDL and Lp(a) Reduction in Severe Hyperlipidemia (DFPP)

DFPP is the historical workhorse for homozygous familial hypercholesterolemia and elevated lipoprotein(a). The selective removal of LDL and Lp(a) (lipoprotein(a), an LDL-like particle with a separate apolipoprotein attachment that independently raises cardiovascular risk) without depleting HDL (high-density lipoprotein, the “good cholesterol” that returns excess cholesterol to the liver) or albumin makes DFPP technically superior to TPE for this indication. Long-term registries from Japan and Europe document sustained 30-year cardiovascular outcome improvements in homozygous FH patients on biweekly DFPP. This is an established, mechanism-aligned use distinct from longevity claims.

Magnitude: A single DFPP session reduces total cholesterol by 40-60% and Lp(a) by 50-70% acutely; biweekly maintenance maintains ~25-35% chronic reduction.

Medium 🟩 🟩

Reduction in Multi-Modal Biological Age Markers (TPE)

The 2025 Fuentealba/Kiprov/Verdin Buck Institute placebo-controlled trial (n=42, NCT06534450) reported that biweekly TPE combined with intravenous immunoglobulin (IVIG, pooled donor antibodies infused to support immune function) produced an average 2.6-year reduction in epigenetic biological age across 15 clocks, accompanied by proteomic and metabolomic shifts. The earlier Kim/Kiprov/Conboy 2022 single-arm study reported similar directional effects. No placebo-controlled DFPP trial in healthy older adults has been published. Evidence is graded Medium because the trial is single-center, small, and conducted by investigators with commercial apheresis affiliations (Global Apheresis Inc.); no DFPP equivalent exists.

Magnitude: ~2.6-year average reduction in epigenetic biological age across 15 clocks (TPE-IVIG arm); placebo-adjusted effect FDR <0.05 (FDR is the false discovery rate, a statistical correction limiting the proportion of false positives across many tests). No equivalent magnitude is established for DFPP.

Reduction in Inflammatory Cytokines and Senescence-Associated Proteins (TPE & DFPP)

Both modalities acutely reduce circulating IL-6 (interleukin-6, an inflammatory signaling molecule), TNF-α (tumor necrosis factor alpha, a master pro-inflammatory cytokine), CRP (C-reactive protein, a general blood marker of systemic inflammation), and a panel of SASP markers. The 2022 Kim et al. study and AMBAR Alzheimer trial substudies (Gonzalo et al. 2024) document this for TPE; DFPP studies in autoimmune and lipid disorders show comparable acute reductions. Whether transient cytokine reductions translate into clinically meaningful longevity outcomes is unproven for either modality.

Magnitude: Acute reductions of 30-60% in CRP, IL-6, and TNF-α immediately post-procedure, with partial rebound within 1-4 weeks for both modalities.

Cognitive Decline Slowing in Mild-to-Moderate Alzheimer’s Disease (TPE) ⚠️ Conflicted

The phase 2b/3 AMBAR trial (Boada et al. 2020, n=347) demonstrated that TPE with albumin replacement slowed Alzheimer’s disease progression on functional and cognitive co-primary endpoints (52% and 66% less decline, respectively, in the moderate-AD subgroup). This is the largest randomized controlled plasma-exchange trial in any non-acute condition. The trial used TPE, not DFPP. ⚠️ Conflicted: the AMBAR investigators report a positive co-primary outcome and a real-world Argentine cohort (Taragano et al. 2025) reports comparable benefit, but the FDA reviewed AMBAR and declined approval, the effect size was modest-to-null in the mild-AD subgroup, and the AMBAR sponsor is the manufacturer of the albumin replacement product (Grifols), so the published positive signal and the regulator’s negative judgment have not been reconciled by an independent replication.

Magnitude: 52-71% less decline in functional/cognitive measures in moderate-AD over 14 months (AMBAR trial).

Low 🟩

Lower Allergy and Donor-Product Burden (DFPP)

In the Liu et al. 2025 retrospective cohort comparing DFPP and TPE for anti-GBM nephritis (n=58), DFPP was associated with significantly fewer allergic episodes (13.6% vs. 42.9%, P=0.049; P is the p-value, the probability that an observed difference occurred by chance, with values below 0.05 conventionally treated as statistically significant) due to reduced exposure to donor albumin or fresh frozen plasma. Hospitalization length, mortality, and antibody reduction were comparable. This is the only published direct head-to-head comparison and is retrospective. In the context of repeat procedures performed over years, this safety-comparison signal favors DFPP, though it has not been replicated in healthy older-adult populations.

Magnitude: ~3-fold lower allergic-event rate in DFPP vs. TPE in the only direct comparison study (anti-GBM nephritis).

Conservation of Coagulation Factors and Immunoglobulins (DFPP)

DFPP retains a larger fraction of patient albumin and a substantial portion of immunoglobulins compared to albumin-replacement TPE, where IgG is depleted by ~60% per session. In contexts of repeated procedures over time, this may translate into a lower cumulative immunological perturbation. Pan et al. 2024 documented that DFPP nonetheless produces measurable coagulation derangement (reduced fibrinogen, prolonged PT (prothrombin time, a clotting test reflecting the extrinsic pathway) and aPTT (activated partial thromboplastin time, a clotting test reflecting the intrinsic pathway)) similar to TPE during the early post-procedure window, so the advantage is graded relative to TPE rather than absolute.

Magnitude: DFPP reduces IgG ~30-40% per session vs. ~55-65% for albumin-replacement TPE; albumin loss <15% for DFPP vs. requirement for full albumin replacement in TPE.

Speculative 🟨

Heavy-Metal and Microplastic Removal

Longevity-clinic marketing materials claim that DFPP and TPE remove circulating heavy metals, microplastics, PFAS (per- and polyfluoroalkyl substances, persistent synthetic chemicals known as “forever chemicals”), and other environmental toxicants. The mechanistic basis is that protein-bound toxicants would be removed alongside the proteins themselves. Published human evidence is limited to small case series and clinic-generated pre/post measurements; no peer-reviewed controlled comparison exists for either modality.

Long-Term Cardiovascular Risk Reduction in Otherwise-Healthy Older Adults

The hypothesis that maintenance plasma-filtration in healthy older adults will reduce hard cardiovascular endpoints is actively debated. Mechanistic plausibility derives from inflammation- and lipid-lowering effects, but no completed long-term outcome trial exists for either modality in this population. Inferences from FH apheresis registries (DFPP/lipoprotein apheresis) and from Buck Institute biomarker data (TPE) cannot substitute for cardiovascular outcome trials.

Differential Effect on Plasma Dilution Mechanism

The Conboy laboratory’s “plasma dilution” paradigm specifically requires dilution of multiple plasma regulators. TPE with albumin replacement clearly accomplishes this; whether DFPP – which preserves more of the patient’s own plasma proteins by design – produces equivalent systemic dilution is mechanistically uncertain. Some authors argue DFPP may produce a smaller longevity signal precisely because of its selectivity. No human study has tested this directly.

Benefit-Modifying Factors

  • Baseline inflammatory and lipid burden: Individuals with elevated CRP, IL-6, Lp(a), or LDL appear to derive larger biomarker shifts from either procedure, with DFPP showing particular advantage where Lp(a) and oxidized-LDL reduction are the goal. Healthy individuals with already-low inflammatory markers may experience smaller or no measurable change.

  • APOE4 carriers: Post-hoc AMBAR analyses suggested APOE4 (an apolipoprotein gene variant strongly associated with Alzheimer’s risk) carriers responded differently to TPE than non-carriers; data are limited and have not been examined for DFPP. APOE4 status may modulate both cognitive and lipid-related outcomes.

  • Sex-based differences: Women tend to have higher baseline IgG and lower fibrinogen than men; the practical implication is that the clinical impact of immunoglobulin depletion (more pronounced in TPE) may differ by sex. No longevity-specific sex-stratified data exist for either modality.

  • Pre-existing autoimmune or lipid disorders: Individuals with established autoimmune disease, familial hypercholesterolemia, or elevated Lp(a) have the strongest mechanism-aligned benefit from one or the other modality (DFPP for lipids; either for autoimmune disease).

  • Age and frailty: Older adults (>70) and those with cardiovascular comorbidities tolerate both procedures less well; the volume shifts inherent to TPE (larger replacement-fluid loads) may pose greater hemodynamic risk in this group than DFPP, which is generally viewed as more volume-neutral.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Hypocalcemia from Citrate Anticoagulation (Both)

Both procedures use citrate (or in some DFPP protocols, heparin or nafamostat mesylate) to prevent extracorporeal clotting. Citrate binds ionized calcium, producing perioral tingling, paresthesias (numbness or pins-and-needles sensations), muscle cramping, and in severe cases tetany (sustained involuntary muscle contractions) or arrhythmia. Severity is mitigated by intra-procedure calcium gluconate infusion. Frequency is high (>50% report mild symptoms) for both modalities; severe events are rare with proper monitoring.

Magnitude: Mild symptoms in 40-60% of sessions; symptomatic hypocalcemia requiring intervention in 5-15%; severe cardiac events <0.1%.

Coagulation Derangement and Bleeding Risk (Both, Worse in DFPP)

Both procedures deplete fibrinogen and clotting factors transiently; DFPP – somewhat counterintuitively – depletes fibrinogen more aggressively per session than TPE because fibrinogen (340 kDa) is preferentially retained on the second filter. Pan et al. 2024 documented sustained reductions of ~50-60% in fibrinogen lasting 24-48 hours after DFPP, with measurable bleeding risk in patients undergoing concurrent invasive procedures. Yeh and Chiu 2001 reported similar findings in serial DFPP. TPE produces somewhat smaller per-session reductions but recovery kinetics depend on replacement fluid (FFP-replaced TPE replenishes clotting factors; albumin-replaced TPE does not).

Magnitude: DFPP: 50-70% acute fibrinogen reduction; TPE with albumin: 30-50%; TPE with FFP: 10-20%. Recovery to baseline in 24-72 hours for both.

Medium 🟥 🟥

Allergic and Anaphylactoid Reactions (Worse in TPE) ⚠️ Conflicted

TPE with FFP replacement carries the highest allergic-reaction rate due to donor-protein exposure (urticaria (an itchy raised hives-like rash), bronchospasm (a sudden tightening of the airways causing wheezing and breathing difficulty), anaphylaxis (a severe, rapidly progressing whole-body allergic reaction with airway swelling, low blood pressure, and shock) reported in 5-10% of FFP-replaced sessions). Anaphylactoid reactions are clinically similar to true anaphylaxis but triggered by direct mast-cell activation rather than IgE-mediated allergy. TPE with albumin replacement has lower reaction rates (1-3%), and DFPP – which uses no donor product when the patient’s own albumin is conserved – has the lowest (0.5-2%). The Liu 2025 cohort study showed 13.6% allergic events in DFPP vs. 42.9% in TPE for anti-GBM nephritis. ⚠️ Conflicted: the magnitude of difference depends heavily on the specific TPE replacement fluid; albumin-only TPE narrows the gap considerably.

Magnitude: DFPP: 1-15%; TPE-albumin: 1-3%; TPE-FFP: 5-10% (of sessions).

Hypotension and Volume Shifts (Worse in TPE)

Both procedures involve extracorporeal blood volumes of 200-400 mL, but TPE typically requires larger replacement-fluid volumes and faster fluid shifts. Hypotensive episodes are reported in 5-10% of TPE sessions and 2-5% of DFPP sessions. Older adults, individuals on antihypertensives, and those with reduced cardiac reserve are at highest risk. Severe hypotension is uncommon but has been associated with myocardial events in vulnerable populations.

Magnitude: Hypotension requiring intervention: TPE 5-10%; DFPP 2-5%.

Vascular Access Complications (Both)

Both procedures require either large-bore peripheral access or a central venous catheter. Catheter-related complications – pneumothorax during insertion, infection, thrombosis – are independent of which modality is performed. For repeated sessions (as in longevity protocols), peripheral access is preferred when feasible. Catheter-related bloodstream infection rates are 1-3 per 1000 catheter-days.

Magnitude: Catheter-related bloodstream infection: 1-3 per 1000 catheter-days; pneumothorax during central-line insertion: <1%.

Low 🟥

Immunoglobulin Depletion and Infection Risk (Worse in TPE)

TPE with albumin replacement depletes IgG by 55-65% per session; multiple sessions can produce sustained hypogammaglobulinemia (an abnormally low blood level of antibodies, IgG <500 mg/dL) and increased infection risk. This is a defining differentiator from DFPP, which removes 30-40% of IgG per session and preserves more host immunoglobulin. Clinically meaningful infection-rate differences between modalities are documented in autoimmune disease cohorts but not in healthy longevity-clinic populations.

Magnitude: Post-TPE serum IgG nadir typically 35-45% of baseline; post-DFPP nadir typically 60-70% of baseline. Recovery over 3-4 weeks.

Citrate Toxicity (Both)

Beyond transient hypocalcemia, severe citrate toxicity (metabolic alkalosis, citrate accumulation in hepatic insufficiency) is rare but can be serious. Bell et al. 2007 documented severe events in volunteer apheresis donors. Both modalities use citrate; DFPP protocols using nafamostat mesylate or heparin avoid citrate-specific issues but introduce other anticoagulant-specific risks.

Magnitude: Severe citrate toxicity <0.1% of sessions; alkalosis or hepatic-insufficiency-related events occur in advanced liver disease populations.

Speculative 🟨

Long-Term Effects of Repeated Plasma Filtration in Healthy Older Adults

Both DFPP and TPE protocols aimed at longevity involve sessions repeated over months to years. Long-term consequences – on hormone-binding globulins, fat-soluble vitamins, micronutrients, and rarer plasma constituents – have not been characterized in healthy populations. Claims that the procedures are “naturally cleansing” lack supporting longitudinal data in this group.

Removal of Beneficial Senescence-Modulating Factors

The plasma factors removed are not all pro-aging; some (klotho, GDF11 controversy notwithstanding, growth factors, signaling proteins) have hypothesized beneficial roles. Indiscriminate removal – particularly with TPE – could in principle deplete beneficial as well as detrimental factors. This concern has been raised in the literature but has not generated demonstrable harm signals in published trials.

Differential Long-Term Cardiovascular Effects

Whether repeated plasma filtration in healthy older adults reduces or increases long-term cardiovascular events is unknown. Lipoprotein-apheresis registries in FH suggest benefit at extreme baseline risk; extrapolation to lower-risk longevity populations is unjustified.

Risk-Modifying Factors

  • Baseline biomarkers (fibrinogen, IgG, ionized calcium): Individuals with low baseline fibrinogen or IgG are at higher risk of post-procedure bleeding or infection-related adverse events; pre-existing borderline hypocalcemia magnifies citrate-related symptoms. Pre-procedure baseline measurement modulates the safety of subsequent sessions for both modalities.

  • Sex-based differences: Women generally have lower baseline plasma volume and lower fibrinogen than men, potentially predisposing to more pronounced volume shifts and earlier hypotensive symptoms during TPE; men more often present with elevated baseline hematocrit and access-thrombosis risk. Specific sex-stratified adverse-event data for either modality in healthy older adults are limited.

  • Replacement fluid choice (TPE): TPE with FFP carries higher allergic and infection risk; TPE with albumin is safer but produces sustained hypogammaglobulinemia. DFPP avoids this trade-off but has its own fibrinogen depletion.

  • Anticoagulant choice (DFPP): DFPP can use citrate, heparin, or nafamostat mesylate. Choice of anticoagulant affects bleeding risk, hypocalcemia frequency, and viability in patients with hepatic insufficiency.

  • Pre-existing coagulopathy (an impairment in the blood’s ability to clot) or thrombocytopenia (an abnormally low platelet count): Both procedures are relatively contraindicated; DFPP’s deeper fibrinogen depletion may make TPE the lesser of two evils when bleeding risk is the primary concern.

  • Cardiovascular reserve and age: Older adults and those with reduced cardiac reserve tolerate volume shifts less well; DFPP is generally lower-volume and may be preferable.

  • APOE4 status: Pharmacogenetic data are limited; APOE4 carriers showed differential responses to TPE in AMBAR. APOE4 (an apolipoprotein gene variant; modifies lipid handling and Alzheimer’s risk) may also influence response to lipid-targeted DFPP.

  • Hepatic insufficiency: Citrate metabolism is impaired in advanced liver disease; nafamostat mesylate is preferred for DFPP in this population.

  • History of allergic reaction to plasma products: Strongly favors DFPP (or autologous-plasma TPE), which avoids donor-product exposure entirely.

Key Interactions & Contraindications

  • ACE inhibitors (a class of blood-pressure medications that block angiotensin-converting enzyme; lisinopril, enalapril, ramipril): Absolute contraindication 24 hours before either procedure when bradykinin-generating filters or columns are used; severe anaphylactoid hypotension reported. Hold for at least 24 hours pre-session.

  • Anticoagulants (warfarin, DOACs which are direct oral anticoagulants that block specific clotting enzymes; apixaban, rivaroxaban, dabigatran): Caution; both procedures further reduce coagulation capacity. Coordinate timing with prescribing physician; may require dose adjustment or temporary discontinuation, particularly for DFPP given deeper fibrinogen depletion.

  • Antiplatelet agents (aspirin, clopidogrel): Caution; cumulative bleeding risk. Continuation depends on indication.

  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs that reduce inflammation and pain by blocking the COX enzymes; ibuprofen, naproxen, diclofenac): Additive bleeding risk through platelet inhibition; pause for 24-72 hours pre-session, particularly relevant before DFPP given deeper fibrinogen depletion.

  • Immunosuppressants (rituximab, corticosteroids, cyclophosphamide): TPE removes the drug along with antibodies if administered close to procedure; timing separation of 12-24 hours is standard. DFPP removes large biological agents (rituximab, IVIG) preferentially over small molecules.

  • Recent IVIG administration: TPE will remove infused IVIG; DFPP will retain a larger fraction. Schedule IVIG after, not before, TPE.

  • Statins, ezetimibe, PCSK9 inhibitors (alirocumab, evolocumab): Synergistic with DFPP for lipid-lowering; not contraindicated but monitoring is required.

  • Supplements with anticoagulant effects: High-dose fish oil (EPA & DHA), Ginkgo biloba, vitamin E, and curcumin extracts may additively increase bleeding risk; pause 1-2 weeks pre-procedure for high doses.

  • Supplements that bind to plasma proteins: Albumin-bound supplements and drugs (phenytoin, thyroid hormone) may have altered kinetics during a course of either procedure.

  • Populations who should avoid both procedures:
    • Hemodynamic instability or shock
    • Active bacteremia (bacterial infection in the bloodstream) or sepsis without source control
    • Severe anemia with hemoglobin <8 g/dL (relative)
    • Inability to obtain safe vascular access
    • Recent (<7 days) myocardial infarction or unstable angina
    • Severe coagulopathy with INR >2.5 (international normalized ratio, a standardized measure of how long blood takes to clot) or platelets <50,000/µL
    • Pregnancy (relative; case-by-case for either modality)
    • Children below ~20 kg body weight (relative; pediatric apheresis is specialized)
  • Populations where DFPP is preferred over TPE:
    • History of plasma-product allergy or anaphylaxis
    • Volume-overload risk (advanced heart failure, NYHA Class III-IV; NYHA is the New York Heart Association functional classification of heart-failure severity)
    • Settings where donor product availability is constrained
    • Severe hyperlipidemia where Lp(a) and LDL are the targets
  • Populations where TPE is preferred over DFPP:
    • TTP and other Category I emergency indications where evidence base is established
    • Severe coagulopathy where minimizing fibrinogen depletion matters
    • Settings without DFPP-trained operators or equipment

Risk Mitigation Strategies

  • Pre-procedure laboratory screening: Obtain CBC (complete blood count), comprehensive metabolic panel (CMP, a standard chemistry panel covering electrolytes, kidney, and liver function), fibrinogen, PT/INR (international normalized ratio, a standardized PT measure), aPTT, ionized calcium, IgG level, and lipid panel before any first session, with abbreviated panels (CBC, fibrinogen, calcium) before each subsequent session. Detects baseline coagulopathy, hypogammaglobulinemia, or electrolyte derangements that increase risk for either modality.

  • Hold ACE inhibitors: Discontinue ACE inhibitors at least 24 hours before any session involving membrane filters or adsorption columns. Prevents bradykinin-mediated anaphylactoid hypotension.

  • Intra-procedure calcium gluconate: Continuous or bolus 10% calcium gluconate (typically 1-2 g per liter of citrate-anticoagulated plasma processed). Mitigates citrate-induced hypocalcemia for both DFPP and TPE.

  • Limit session frequency to physiological recovery curves: For longevity protocols, space sessions ≥ 1-2 weeks for DFPP (to allow fibrinogen and IgG recovery) and ≥ 2 weeks for TPE. Prevents cumulative coagulopathy and immunoglobulin depletion.

  • Replacement fluid selection: For TPE, prefer 5% albumin in saline over FFP unless specific clotting-factor replacement is needed; reduces allergic-reaction risk by 5-10× compared to FFP-based TPE.

  • Vascular access selection: Prefer peripheral large-bore access (16-18G) over central venous catheter when anatomically feasible, particularly for long-term longevity protocols; reduces catheter-related bloodstream infection and thrombosis.

  • Operator and facility credentialing: Procedures should be performed by ASFA-credentialed apheresis nurses or physicians (ASFA membership derives direct revenue from performing the procedures it credentials) at facilities with adverse-event response protocols. Off-protocol “longevity” providers may not meet these standards; verify before proceeding.

  • Post-procedure monitoring: Vital signs every 15 minutes for the first hour, fibrinogen and ionized calcium check 6-24 hours post-procedure for high-risk individuals. Detects delayed hypocalcemia, hypotension, or bleeding.

  • Trough IgG monitoring for repeat TPE: For protocols involving >4 sessions in 12 months, check IgG trough levels every 2-3 sessions; consider IVIG supplementation or modality switch to DFPP if IgG drops below 500 mg/dL. Reduces hypogammaglobulinemia-related infection risk.

  • Hold antiplatelets and anticoagulants per cardiology guidance: When safely feasible, pause agents that compound bleeding risk for 24-72 hours pre-procedure. Reduces bleeding complications, particularly during DFPP fibrinogen nadir.

Therapeutic Protocol

The standard protocols differ by indication; longevity protocols are non-standardized and remain investigational. The descriptions below reflect protocols used by leading apheresis specialists and clinical-trial regimens, not consensus medical recommendations.

  • Pre-procedure assessment: Comprehensive history, baseline labs, ACE inhibitor hold for 24-48 hours, vascular-access plan. Reviewed by an ASFA-credentialed physician.

  • TPE longevity protocol (Buck Institute / Kiprov): 1-1.5 plasma volumes per session (~3-4 L for an average adult), 5% human albumin replacement, biweekly for 6-8 sessions, optionally combined with low-dose IVIG. The 2025 Fuentealba/Verdin trial used this regimen with statistically significant biological-age effects.

  • TPE Alzheimer protocol (AMBAR / Grifols): 6 weekly conventional TPE sessions followed by 12 months of monthly low-volume plasma exchange (PE, ~1 L), with albumin and IVIG replacement. Used in the AMBAR phase 2b/3 trial.

  • DFPP autoimmune/lipid protocol (Japanese / European): 1.5-2 plasma volumes processed, no donor replacement (or partial albumin), citrate or nafamostat anticoagulation, biweekly for the acute course, monthly for maintenance. Used in homozygous FH and several autoimmune indications.

  • DFPP longevity protocol (longevity-clinic, non-standardized): 1-1.5 plasma volumes processed, monthly to quarterly. There is no published controlled trial of any specific DFPP longevity regimen; clinic protocols vary widely in volume, anticoagulation, and frequency.

  • Best time of day: Either procedure is typically scheduled in the morning to allow same-day post-procedure observation. No circadian-pharmacology data favor one time over another.

  • Half-life and dosing rationale: Because IgG re-equilibrates over 3-4 weeks and fibrinogen over 3-5 days, sessions spaced more closely than 1 week may produce cumulative depletion. Sessions spaced more than 4 weeks apart may not maintain target reductions.

  • Single vs. split sessions: Both are typically delivered as a single session per visit, lasting 1.5-3 hours.

  • Genetic polymorphisms: APOE4 (an apolipoprotein gene variant influencing lipid handling and Alzheimer’s risk) has been suggested to influence cognitive response to TPE in AMBAR post-hoc analyses; relevance to DFPP is unstudied. PCSK9 (a gene encoding the enzyme that regulates the breakdown of LDL receptors and thus blood LDL levels) and LDLR (the gene for the LDL receptor itself, the cellular machinery that clears LDL from blood) variants relevant to lipid disorders may influence DFPP lipid response.

  • Sex-based differences: No major sex-stratified longevity protocol differences are established. Women may experience earlier perceived volume effects due to lower baseline plasma volume.

  • Age-related considerations: Older adults (>70) and those with cardiovascular comorbidities are typically managed with smaller per-session plasma volumes (1.0× rather than 1.5×) and slower flow rates; DFPP is sometimes preferred for hemodynamic reasons.

  • Baseline biomarker considerations: Individuals with elevated CRP, IL-6, Lp(a), or LDL appear to derive larger biomarker shifts. Those with already-low markers may experience smaller effects.

  • Pre-existing health conditions: Heart failure, recent myocardial infarction, severe anemia, or active infection may delay or contraindicate either procedure; protocol modifications by an apheresis specialist are required.

  • Modality choice within a protocol: No published protocol formally combines DFPP and TPE within a single longevity course. The Pilot study NCT06571552 is currently testing single TPE followed by DFPP for hyperfibrinogenemia (abnormally elevated fibrinogen levels).

Discontinuation & Cycling

  • Lifelong vs. short-term: Neither modality is intended as a discrete short course in the longevity context; longevity-clinic protocols envision indefinite intermittent maintenance, while medical indications (TTP, GBS, MG crisis, FH) have well-defined acute and chronic regimens. The optimal long-term cadence for healthy individuals is unestablished for both DFPP and TPE.

  • Withdrawal effects: Neither procedure produces classical pharmacological withdrawal. Removed plasma factors return to baseline over weeks; biomarker reductions are reversed within 1-3 months in the absence of repeat sessions. The 2022 Kim et al. study reported partial persistence of biomarker effects 2-3 months post-protocol; longer-term durability is unmeasured.

  • Tapering: Not typically employed for either modality; sessions are spaced or discontinued without taper.

  • Cycling considerations: Most protocols reflect cycling implicitly: an acute course followed by maintenance at lower frequency. Whether continuous low-frequency maintenance is superior to intermittent intensive courses is unstudied for both modalities.

  • Long-term consequences of discontinuation: Unknown for either modality in healthy populations; biomarker rebound to baseline is expected based on plasma-protein kinetics.

Sourcing and Quality

  • Facility credentialing: Both procedures require an ASFA-credentialed apheresis center with appropriate device licensure (FDA-cleared in the US) and trained personnel. Verify ASFA credentialing of operators (noting that ASFA’s membership derives direct revenue from these procedures) and review the center’s adverse-event protocol.

  • Equipment manufacturers (TPE): Centrifugal devices (Spectra Optia by Terumo BCT; previously COBE Spectra) and membrane systems (Fresenius multiFiltrate, Diapact) dominate. Independent device-comparison data (Keklik et al. 2022) show comparable plasma-removal efficiency between centrifugal and membrane TPE.

  • Equipment manufacturers (DFPP): Asahi Plasmaflo separators paired with Cascadeflo or Evaflux fractionators are the most-used commercial systems; alternatives include Toray and Kawasumi devices. DFPP equipment is more available in Japan, Italy, China, and Germany than in the US.

  • Replacement fluids (TPE): 5% human albumin (Albutein, Flexbumin, generics) sourced from FDA-licensed plasma collectors with viral-inactivation chains. Verify pharmaceutical-grade, infectious-disease-tested origin; avoid cosmetic or nutraceutical “albumin” products which are not appropriate.

  • Replacement fluids (DFPP): Where partial albumin replacement is used, the same standards apply; many DFPP protocols use no donor replacement.

  • Anticoagulants: Citrate (ACD-A) is widely available; nafamostat mesylate is preferred in some DFPP protocols and has limited US availability. Heparin alternatives may be used.

  • Cost and accessibility: TPE for medical indications is widely available in academic centers and reimbursed by insurance. Longevity-clinic TPE/DFPP is largely cash-pay; sessions range from $1,200 to $10,000+ in the US, with TPE protocols (particularly biweekly/monthly multi-session courses) often totaling $20,000-$50,000+. DFPP is less expensive in countries where the equipment is standard. Because US insurers and national health systems reimburse TPE under existing apheresis billing codes but do not cover DFPP for most indications outside lipid disorders, payers have a structural incentive favoring TPE in clinical settings; this asymmetry plausibly biases North American guideline development and research funding toward TPE and away from DFPP, independent of comparative efficacy evidence.

  • Clinics and operators of note: Dr. Dobri Kiprov (Apheresis Care Group, Mill Valley CA) is the most-cited longevity-TPE practitioner; his clinic has collaborated on most published longevity-TPE studies. Several US, European, and Asian clinics offer DFPP under variable longevity branding, but no published longevity-trial leadership has emerged from the DFPP side.

Practical Considerations

  • Time to effect: Acute biomarker changes (cytokines, lipids) appear within hours to 1-2 days; biological-age clock changes have been reported at the end of multi-session courses (2-4 months). Persistence beyond 3 months is not well-characterized.

  • Common pitfalls:
    • Selecting modality based on clinic marketing rather than mechanism alignment with the goal
    • Underestimating cumulative cost of multi-session protocols
    • Failing to coordinate with treating physicians regarding medication timing (TPE removes drugs)
    • Skipping baseline laboratory assessment, particularly of coagulation and immunoglobulin levels
    • Treating either procedure as a substitute for foundational lifestyle interventions
    • Assuming “selective” DFPP is automatically safer than “non-selective” TPE; both have distinct risk profiles

  • Regulatory status: Both DFPP and TPE devices are FDA-cleared for specific medical indications. Longevity use is off-label in the United States. ASFA-graded indications do not include “biological age reduction” or “anti-aging” as approved categories. Many longevity clinics operate under broader “wellness” registrations.

  • Cost and accessibility: Longevity protocols are cash-pay in most jurisdictions; total costs of $20,000-$100,000 over a year are typical. Insurance does not cover longevity indications. Geographic access is uneven: TPE is widely available; DFPP is concentrated in Asia and parts of Europe, with limited US availability.

  • Downtime and recovery: Most participants resume normal activity the same or following day; bruising at access sites and transient fatigue are common.

Interaction with Foundational Habits

  • Sleep: No direct interaction in either direction. Anecdotal reports of improved sleep quality post-procedure have been published but are not validated in controlled studies; mechanism would presumably be inflammation reduction.

  • Nutrition: Adequate hydration before and after sessions is standard. Protein intake should be sufficient to support albumin recovery (typically not problematic with normal diets). Both procedures may transiently lower fat-soluble vitamin levels (vitamin K, vitamin D) bound to lipoproteins, particularly DFPP given its lipid-removal selectivity; supplementation is sometimes recommended after multi-session courses. Calcium-rich intake supports recovery from citrate-related transient hypocalcemia.

  • Exercise: No direct potentiation or blunting effect. Strenuous exercise within 24-48 hours of either procedure is typically discouraged given transient hemodynamic and coagulation derangement; resume normal training thereafter. No data favor one modality over the other regarding exercise interaction.

  • Stress management: No documented direct effect on cortisol or HPA (hypothalamic-pituitary-adrenal, the body’s central stress-response circuit linking the brain to the adrenal glands) axis function. The procedures themselves are mildly stressful and time-consuming (1.5-3 hours per session); incorporating stress-reduction practices around session days may improve subjective tolerance.

Monitoring Protocol & Defining Success

Baseline biomarker assessment should be completed before any first session and at periodic intervals across a course of either modality. Quantitative markers reflect both safety (coagulation, immunoglobulin status) and putative efficacy (biological age, inflammation, lipids).

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fibrinogen 200-400 mg/dL Coagulation safety; depleted more by DFPP Check pre/post each session for first course; nadir 6-24 hr post-DFPP
Platelets 175-300 ×10⁹/L Coagulation safety; modestly reduced by both Conventional reference 150-400; functional optimum narrower
PT/INR INR 0.9-1.2 Coagulation safety Check pre-session for high-risk individuals
aPTT 25-35 seconds Coagulation safety Same as PT
Ionized calcium 1.10-1.30 mmol/L Citrate-related hypocalcemia detection Check intra- and post-procedure for symptomatic individuals
IgG >800 mg/dL Immunoglobulin depletion (TPE > DFPP) Conventional reference 700-1600; functional ≥800 to limit infection risk
Albumin 4.2-5.0 g/dL Protein status; replacement adequacy (TPE) Conventional 3.5-5.0; functional optimum 4.2-5.0
hs-CRP <1.0 mg/L Inflammation; both modalities reduce acutely Standard inflammation marker
IL-6 <2 pg/mL Inflammation; both modalities reduce acutely Less standard; specialized lab
LDL cholesterol <100 mg/dL (longevity goals often <70) Lipid response (DFPP > TPE) Conventional <130; functional/longevity tighter; 9-12 hour fasting required for accurate lipid panel; pair with Lp(a) and ApoB (apolipoprotein B, the structural protein on each LDL particle and a more direct count of atherogenic particles than LDL-C alone)
Lipoprotein(a) <30 mg/dL or <75 nmol/L Lipid response (DFPP particularly) DFPP is uniquely effective; fasting not strictly required; once-in-a-lifetime test unless intervention modifies it
Epigenetic age (Horvath, GrimAge, PhenoAge) Below chronological age Putative longevity efficacy Research-grade; commercial tests vary in reliability; collect at consistent time of day
Comprehensive metabolic panel Within reference range General safety Includes electrolytes, kidney, liver function; 8-12 hour fasting recommended for accurate glucose and lipid components
CBC with differential Within reference range Anemia, infection screening Pre-session screening; not fasting-dependent; collect morning when paired with other fasting labs

Ongoing monitoring cadence: baseline, immediately post-first session (24 hours), then before each subsequent session for the first course, with a comprehensive panel after every 4 sessions or every 6 months on maintenance. Epigenetic-age testing is typically done at baseline, end of acute course (~2-4 months), and 6-12 months thereafter.

Qualitative markers to track:

  • Subjective energy and fatigue
  • Cognitive clarity and focus
  • Sleep quality
  • Recovery from physical training
  • Joint stiffness or inflammation symptoms
  • Adverse-event symptoms (paresthesias, bruising, dizziness)

Defining success: at the level of biomarkers, sustained reductions in inflammatory and lipid markers (or in epigenetic age clocks) maintained beyond the immediate post-procedure period. At the level of subjective experience, improvements in energy, cognition, or recovery without adverse-event accumulation. The absence of long-term outcome data means that “success” remains a biomarker- and experience-based construct, not a hard-endpoint construct, for either modality in the longevity context.

Emerging Research

  • Major ongoing or recent trials:
    • Buck Institute TPE longevity trial: NCT06534450 — Active, not recruiting; phase 3, n=42; sham-controlled comparison of biweekly TPE, TPE+IVIG, and monthly TPE on epigenetic clocks and aging biomarkers. Primary results published 2025 (Fuentealba et al., Aging Cell).
    • Plasmapheresis with vs. without albumin replacement for aging biomarkers: NCT04897113 — Status unknown; n=80; compares TPE-with-albumin vs. TPE-without-albumin in adults 40-55 years.
    • Effects of Plasmapheresis on Aging Biomarkers: NCT05004220 — Completed; n=41; published in 2025 by Borsky et al. as a two-arm cross-over study (8 vs. 4 plasmapheresis sessions over 18 weeks, no young-plasma or albumin volume replacement) in healthy donors (Sci Rep). Notably, no epigenetic rejuvenation was observed; the protocol was associated with increases in DNAmGrimAge, the Hannum clock, and the Dunedin Pace of Aging — a result that diverges from the Buck Institute findings and underscores how protocol design (replacement fluid, session frequency) may determine direction of effect.
    • DFPP vs. PFS coagulation comparison pilot: NCT06571552 — Recruiting; n=6; pilot descriptive study of coagulation after sequential plasma exchange and DFPP (PFS = plasma filtration system, the trial’s term for conventional membrane-based therapeutic plasma exchange). The only registered trial directly comparing DFPP-related coagulation kinetics to standard plasma exchange.

  • AMBAR follow-up and real-world TPE: Real-world TPE in Alzheimer’s disease (Taragano et al. 2025) and AMBAR substudies on neuroimaging (Cuberas-Borrós et al. 2022) and inflammatory mediators (Gonzalo et al. 2024) are extending the AMBAR signal but have not produced FDA approval.

  • DFPP pleiotropic effects: Hirano and Namazuda 2024 reviewed pleiotropic (off-target) effects of DFPP including changes in oxidative stress markers, microvascular function, and inflammation. This review-level work begins to scaffold a longevity-oriented evidence base for DFPP, though no longevity outcome trial is underway.

  • Direct DFPP vs. TPE cohort: Liu et al. 2025 provides the only published direct head-to-head outcome comparison (in anti-GBM nephritis); no such comparison exists in healthy older adults.

  • Areas of future research that could change current understanding:
    • Whether DFPP can match TPE on epigenetic-age outcomes despite its lower-volume, more selective approach — direct comparison would extend the head-to-head signal from Liu et al. 2025 (anti-GBM nephritis) into the longevity setting
    • Whether either modality reduces hard cardiovascular or all-cause mortality endpoints in healthy older adults; outcome trials going beyond the biomarker findings of Fuentealba et al. 2025 are absent
    • Long-term safety of repeated multi-year protocols, particularly cumulative immunoglobulin depletion (more relevant to TPE) — relevant baseline given the divergent epigenetic findings of Borsky et al. 2025
    • Mechanistic clarification of which removed factors are responsible for biomarker shifts; pleiotropic-effects work such as Hirano and Namazuda 2024 provides a starting catalogue for DFPP
    • Optimal session frequency, volume, and replacement fluid for longevity outcomes; the dose-response space tested by Fuentealba et al. 2025 and Borsky et al. 2025 covers only a fraction of plausible regimens
    • Cost-effectiveness vs. simpler interventions (e.g., aggressive lipid management, anti-inflammatory lifestyle) producing comparable biomarker effects

  • Studies that could weaken the case: Long-term registries showing infection or neoplasia accumulation following years of either procedure; null replications of the Buck Institute TPE biological-age findings in independent placebo-controlled trials.

  • Studies that could strengthen the case: Independent multi-center placebo-controlled trials replicating the Fuentealba/Verdin TPE biomarker results; first published placebo-controlled DFPP longevity trial demonstrating comparable or superior biomarker shifts at lower per-session burden.

Conclusion

Double filtration plasmapheresis and therapeutic plasma exchange are mechanistically related but operationally distinct procedures that share a longevity rationale – removal of age-elevated plasma factors – while offering different trade-offs. The plasma-exchange approach has the larger evidence base, including the only placebo-controlled trial reporting reductions in epigenetic biological age and the only large randomized trial in a chronic neurodegenerative condition. The double-filtration approach has the longer safety record in repetitive use, particularly for severe lipid disorders, and the only published direct comparison shows comparable efficacy with fewer allergic reactions, less donor-product exposure, and preservation of host albumin and immunoglobulins – offset by deeper fibrinogen depletion.

For longevity applications, the supporting evidence comes almost exclusively from plasma-exchange studies, all small, single-center, and led by investigators with apheresis-industry affiliations; the principal professional society endorsing both procedures derives direct revenue from its members performing them, and institutional payer reimbursement structures favor plasma exchange over double filtration in North America. Translation to the double-filtration approach rests on mechanistic similarity rather than direct trial data. The available evidence does not yet establish whether either modality produces durable health-span benefits beyond transient biomarker shifts.

Both procedures carry substantive procedural risks, require credentialed operators, and entail meaningful financial commitment over a multi-session course. The choice between them is best framed as a comparison of distinct risk and access profiles aligned with individual baseline biology, rather than as a contest between an established and an emerging modality.

Top - Benefits - Risks - Protocol